BRAF and neoplasm: In deciding whether to use a targeted treatment for melanoma in the adjuvant setting, either for stage III or stage IIB-C, it is important to consider whether the tumor cells that avoid surgical resection, presumably due to early metastasis, would continue to harbor the mutation being targeted (e.g., BRAF).